Abstract
The use of daptomycin (DAP) in septic pulmonary emboli (SPE) remains controversial. We analyzed 29 cases of MRSA bacteremia complicated by SPE treated with DAP (n = 14) or DAP-ceftaroline fosamil (CPT; n = 15). Initial treatment with DAP monotherapy was found to have a success rate comparable with DAP-CPT (71% vs. 80%; p = 0.68).
Similar content being viewed by others
Data availability
The data and material are available upon request.
References
Centers for Disease Control and Prevention (CDC). Antibiotic resistance threats in the United States, 2019. Available from: https://www.cdc.gov/drugresistance/pdf/threats-report/2019-ar-threats-report-508.pdf. Accessed November 14, 2019.
van Hal SJ, Fowler VG Jr (2013) Is it time to replace vancomycin in the treatment of methicillin-resistant Staphylococcus aureus infections? Clin Infect Dis 56:1779–1788
Goswami U, Brenes JA, Punjabi GV, LeClaire MM, Williams DN (2014) Associations and outcomes of septic pulmonary emboli. Open Respir Med J 8:28–33
Silverman JA, Mortin LE, VanPraagh ADG, Li T, Alder J (2005) Inhibition of daptomycin by pulmonary surfactant: in vitro modeling and clinical impact. J Infect Dis 191:2149–2152
Crass RL, Powell KL, Huang AM (2019) Daptomycin for the treatment of Staphylococcus aureus infections complicated by septic pulmonary emboli. Diagn Microbiol Infect Dis 93:131–135
Wong D, Chandraratna AN, Wishnow RM, Dusitnanond V, Nimalasuriya A (1983) Clinical implications of large vegetations in infectious endocarditis. Arch Intern Med 143:1874–1877
Rehm SJ, Boucher H, Levine D et al (2008) Daptomycin versus vancomycin plus gentamicin for treatment of bacteraemia and endocarditis due to Staphylococcus aureus: subset analysis of patients infected with methicillin-resistant isolates. J Antimicrob Chemother 62:1413–1421
Kanafani Z, Boucher H, Fowler V et al (2010) Daptomycin compared to standard therapy for the treatment of native valve endocarditis. Enferm Infecc Microbiol Clin 28:498–503
Werth BJ, Sakoulas G, Rose WE, Pgliano J, Tewhey R, Rybak MJ (2013) Ceftaroline increases membrane binding and enhances the activity of daptomycin against daptomycin-nonsusceptible vancomycin-intermediate Staphylococcus aureus in a pharmacokinetic/pharmacodynamics model. Antimicrob Agents Chemother 57:66–73
Geriak M, Haddad F, Rizvi K et al (2019) Clinical data on daptomycin plus ceftaroline versus standard of care monotherapy in the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 63. https://doi.org/10.1128/AAC.02483-18
Fowler VG Jr, Boucher HW, Corey GR et al (2006) Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med 355:653–665
Harada Y, Yanagihara K, Yamada K et al (2013) In vivo efficacy of daptomycin against methicillin-resistant Staphylococcus aureus in a mouse model of hematogenous pulmonary infection. Antimicrob Agents Chemother 57:2841–2844
Kephart PA, Esposito AL (1988) Comparison of the investigational drug, LY146032, with vancomycin in experimental pneumonia due to methicillin-resistant Staphylococcus aureus. J Antimicrob Chemother 21:33–39
Verghese A, Haire C, Franzus B, Smith K (1988) LY146032 in a hamster model of Staphylococcus aureus pneumonia—effect on in vivo clearance and mortality and in vitro opsonophagocytic killing. Chemotherapy 34:497–503
Heine HS, Basset J, Miller L, Purcell BK, Byrne WR (2010) Efficacy of daptomycin against Bacillus anthracis in a murine model of anthrax spore inhalation. Antimicrob Agents Chemother 54:4471–4473
Pertel PE, Bernardo P, Fogarty C et al (2008) Effects of prior effective therapy on the efficacy on daptomycin and ceftriaxone for the treatment of community-acquired pneumonia. Clin Infect Dis 46:1142–1151
Hagiya H, Hagioka S, Otsuka F (2013) Ineffectiveness of daptomycin in the treatment of septic pulmonary emboli and persistent bacteremia caused by methicillin-resistant Staphylococcus aureus. Intern Med 52:2577–2582
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
MJR has received grant support, consulted, or spoken on behalf of Accelerate, Allergan, Bayer, Melinta, Merck, Motif, Nabriva, Paratek, Qupex, Shionogi, and Tetraphase, and he is partially supported by NIH R01 Al12400. TM, AML, and SA have no conflicts of interest to disclose.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Morrisette, T., Lagnf, A.M., Alosaimy, S. et al. A comparison of daptomycin alone and in combination with ceftaroline fosamil for methicillin-resistant Staphylococcus aureus bacteremia complicated by septic pulmonary emboli. Eur J Clin Microbiol Infect Dis 39, 2199–2203 (2020). https://doi.org/10.1007/s10096-020-03941-5
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10096-020-03941-5